| Title |
Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, September 2021
|
| DOI | 10.1158/1535-7163.mct-21-0071 |
| Pubmed ID | |
| Authors |
Megan E. Zavorka Thomas, Xiyuan Lu, Zahra Talebi, Jae Yoon Jeon, Daelynn R. Buelow, Alice A. Gibson, Muhammad Erfan Uddin, Lindsey T. Brinton, Julie Nguyen, Meghan Collins, Alessia Lodi, Shannon R. Sweeney, Moray J. Campbell, Douglas H. Sweet, Alex Sparreboom, Rosa Lapalombella, Stefano Tiziani, Sharyn D. Baker |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 38% |
| Germany | 2 | 13% |
| Unknown | 8 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 50% |
| Scientists | 7 | 44% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 27% |
| Student > Ph. D. Student | 3 | 14% |
| Lecturer > Senior Lecturer | 1 | 5% |
| Student > Bachelor | 1 | 5% |
| Other | 1 | 5% |
| Other | 2 | 9% |
| Unknown | 8 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 9 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Nursing and Health Professions | 1 | 5% |
| Immunology and Microbiology | 1 | 5% |
| Medicine and Dentistry | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 9 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2021.
All research outputs
#3,740,756
of 23,310,485 outputs
Outputs from Molecular Cancer Therapeutics
#706
of 3,902 outputs
Outputs of similar age
#81,534
of 430,039 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#9
of 44 outputs
Altmetric has tracked 23,310,485 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,902 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 430,039 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.